Clinical Trial Update: Sutent Adjunctive Treatment of Differentiated Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Sutent as adjunctive therapy for differentiated thyroid cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer
• Follicular Thyroid Cancer
• Papillary Thyroid Cancer

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Medstar Health Research Institute | Conditions: Papillary Thyroid Cancer, Follicular Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-04-18